文献速递肿瘤 PET/CT

局部晚期黏膜原发头颈部鳞状细胞癌放疗期间FDG PET/CT的淋巴结参数可预测治疗结局:SUVmean与缓解率是有用的影像生物标志物

Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2016-12-21

纳入75例新诊断局部晚期淋巴结阳性黏膜原发头颈部鳞状细胞癌患者,在放疗前及放疗第3周行FDG PET/CT,评估淋巴结代谢参数与3年生存结局的关系。多因素分析显示,放疗中索引淋巴结SUVmean(最优截断值2.95 g/ml)和总淋巴结SUVmean(最优截断值3.25)是独立预测因子,总淋巴结TLG下降超过50%是局部区域和远处无失败生存、无病生存及总生存的最佳生物标志物。放疗前淋巴结参数与肿瘤学结局无显著相关。

要点

  • 放疗第3周索引淋巴结SUVmean(截断值2.95 g/ml)与总淋巴结SUVmean(截断值3.25)为独立预后预测因子。
  • 总淋巴结TLG下降超过50%是局部区域和远处无失败生存、无病生存及总生存的最佳生物标志物。
  • 放疗前淋巴结代谢参数与肿瘤学结局无显著相关。

核心结论

  • 放疗中索引淋巴结和总淋巴结SUVmean及MTV和TLG下降超过50%是有用的影像生物标志物,可能识别局部区域转移失败和死亡高风险的黏膜原发头颈部鳞状细胞癌患者。

研究设计与样本

  • 纳入75例新诊断局部晚期淋巴结阳性黏膜原发头颈部鳞状细胞癌患者,接受根治性放疗和同期全身治疗,放疗前及放疗第3周行FDG PET/CT;N1 11例、N2a 38例、N2b 12例、N2c 9例、N3 5例;中位随访28个月(9-70个月)。

主要发现

  • 多因素分析中,放疗中索引淋巴结SUVmean(最优截断值2.95 g/ml)对无病生存和总生存的p值分别为0.033和0.003。
  • 放疗中总淋巴结SUVmean(最优截断值3.25)对局部区域无失败生存、无病生存和总生存的p值分别为0.028、0.025和0.014。
  • 总淋巴结TLG下降超过50%对局部区域无失败生存、区域无失败生存、无病生存和总生存的p值分别为0.001、0.016、0.001和0.004。
  • 总淋巴结MTV下降对局部区域无失败生存、无病生存和总生存的p值分别为0.026、0.003和0.014。
  • 放疗前淋巴结参数与肿瘤学结局无显著相关。

关键数值与推荐

  • 索引淋巴结SUVmean最优截断值2.95 g/ml。
  • 总淋巴结SUVmean最优截断值3.25。
  • 总淋巴结TLG下降超过50%为局部区域和区域无失败生存、无病生存及总生存的最佳生物标志物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the prognostic utility of nodal metabolic parameters derived from FDG PET/CT performed before radiotherapy (prePET) and during the third week of radiotherapy (iPET) in patients with mucosal primary head and neck squamous cell carcinoma (MPHNSCC). METHODS: This analysis included 75 patients with newly diagnosed locally advanced node-positive MPHNSCC treated with radical radiotherapy and concurrent systemic therapy who underwent prePET and iPET: N1 11 patients, N2a 38, N2b 12, N2c 9, N3 5. The median follow-up was 28 months (9 - 70 months). The maximum and mean standardized uptake values (SUVmax and SUVmean), metabolic tumour volume (MTV) and total lesional glycolysis (TLG) of the index lymph node (node with the highest TLG) and the combined total lymph nodes, and their percentage reductions on iPET were determined, and the results were correlated with 3-year Kaplan-Meier locoregional, regional and distant metastatic failure-free survival (FFS), disease-free survival (DFS) and overall survival (OS). Optimal cut-off values were derived from receiver operating characteristic curves. Cox regression univariate and multivariate analyses with clinical covariates were performed. RESULTS: Based on assessment of residual nodal metabolic burden during treatment, the iPET index node SUVmean (optimal cut-off value 2.95 g/ml) and the total node SUVmean (optimal cut-off value 3.25) were the best independent predictors of outcome in the multivariate analysis: index node SUVmean for DFS and OS p = 0.033 and 0.003, respectively, and the total node SUVmean for locoregional FFS, DFS and OS p = 0.028, 0.025 and 0.014, respectively. Based on the assessment of response rates during treatment, a reduction of more than 50 % in the total node TLG was the best biomarker for locoregional and regional FFS, DFS and OS in the multivariate analysis (p = 0.001, 0.016, 0.001 and 0.004, respectively), and reduction in the total node MTV for locoregional FFS, DFS and OS (p = 0.026, 0.003 and 0.014, respectively). There were no significant correlations between oncological outcomes and prePET nodal parameters. CONCLUSION: We demonstrated that the index node and total node SUVmean on iPET and a reduction of more than 50 % in MTV and TLG are useful imaging biomarkers, and can potentially identify those patients with MPHNSCC who have a high risk of locoregional metastatic failure and death.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lin P, Min M, Lee M, et al. Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers. Eur J Nucl Med Mol Imaging. 2016. PMID: 28004135. doi:10.1007/s00259-016-3584-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。